CytoAgents CEO, Teresa Whalen, RPh spoke with Bill Flanagan at WPXI-TV about our lead drug candidate GP1681 entering clinical trials. She discussed how GP1681 is designed to calm the “cytokine storm,” a condition triggered by COVID-19, influenza, and other respiratory viruses. Often, the cytokine storm causes more damage then the viruses themselves.